company background image
TDOC

Teladoc HealthNYSE:TDOC Stock Report

Last Price

US$72.03

Market Cap

US$11.5b

7D

-4.8%

1Y

-74.8%

Updated

26 Jan, 2022

Data

Company Financials +
TDOC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

TDOC Stock Overview

Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally.

Teladoc Health Competitors

Cerner

NasdaqGS:CERN

US$26.8b

GoodRx Holdings

NasdaqGS:GDRX

US$9.6b

Doximity

NYSE:DOCS

US$8.0b

Allscripts Healthcare Solutions

NasdaqGS:MDRX

US$2.5b

Price History & Performance

Summary of all time highs, changes and price drops for Teladoc Health
Historical stock prices
Current Share PriceUS$72.03
52 Week HighUS$308.00
52 Week LowUS$66.93
Beta0.34
1 Month Change-24.25%
3 Month Change-48.04%
1 Year Change-74.84%
3 Year Change18.55%
5 Year Change260.15%
Change since IPO152.74%

Recent News & Updates

Jan 26

Teladoc: A Healthcare Stock Worth Considering Today

Teladoc shares recently broke a new 52-week low and are down 74% in the past year. Teladoc's decline in share price is part of a larger downward trend in high growth tech companies as a result of rising interest rates and inflation. The global telehealth market is forecasted to reach over $500 billion by 2028, leaving Teladoc well-positioned given its status as a pioneer in the virtual medicine space. As competition continues to heat up, Teladoc will have to fend off newcomers, traditional healthcare companies, and even tech giants like Amazon.

Jan 19

What Does Competition From Amazon Care Mean To Teladoc?

As Amazon Care continues to expand its virtual healthcare offerings, it will offer a similar range of services to Teladoc, as well as providing in-person care and prescription delivery services. Amazon Care is indeed taking the virtual healthcare market by storm, with its considerable cash and equivalents of $29.9B, compared to $823.8M for TDOC. As competition heats up, consensus estimates suggest that there is enough room in the personalized healthcare market for multiple major players moving forward. We discuss whether investors should add TDOC stock now.

Jan 11
Prevalent Insider Selling Confirms the Teladoc Health's (NYSE:TDOC) Decline

Prevalent Insider Selling Confirms the Teladoc Health's (NYSE:TDOC) Decline

It is often said that the market takes a staircase up and an elevator down, but in some cases, stocks can take an elevator both ways. Such was the case with Teladoc Health. Over the last 2 years, it rose over 250% just to give back all the gains and return to the starting line.

Shareholder Returns

TDOCUS Healthcare ServicesUS Market
7D-4.8%-2.2%-5.1%
1Y-74.8%-37.0%3.3%

Return vs Industry: TDOC underperformed the US Healthcare Services industry which returned -35.5% over the past year.

Return vs Market: TDOC underperformed the US Market which returned 4.2% over the past year.

Price Volatility

Is TDOC's price volatile compared to industry and market?
TDOC volatility
TDOC Average Weekly Movement8.8%
Healthcare Services Industry Average Movement10.0%
Market Average Movement6.7%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.4%

Stable Share Price: TDOC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: TDOC's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20024,026Jason Gorevichttps://www.teladochealth.com

Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, chronic condition management, expert medical services, behavioral health solutions, guidance and support, and platform and program services. It serves health employers, health plans, hospitals, health systems, and insurance and financial services companies.

Teladoc Health Fundamentals Summary

How do Teladoc Health's earnings and revenue compare to its market cap?
TDOC fundamental statistics
Market CapUS$11.53b
Earnings (TTM)-US$811.77m
Revenue (TTM)US$1.86b

6.2x

P/S Ratio

-14.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TDOC income statement (TTM)
RevenueUS$1.86b
Cost of RevenueUS$598.22m
Gross ProfitUS$1.26b
ExpensesUS$2.08b
Earnings-US$811.77m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-5.07
Gross Margin67.87%
Net Profit Margin-43.60%
Debt/Equity Ratio7.7%

How did TDOC perform over the long term?

See historical performance and comparison

Valuation

Is Teladoc Health undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TDOC ($72.03) is trading below our estimate of fair value ($229.85)

Significantly Below Fair Value: TDOC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TDOC is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.

PE vs Market: TDOC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TDOC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TDOC is good value based on its PB Ratio (0.7x) compared to the US Healthcare Services industry average (3.4x).


Future Growth

How is Teladoc Health forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?

44.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TDOC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TDOC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TDOC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TDOC's revenue (21.4% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: TDOC's revenue (21.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TDOC's Return on Equity is forecast to be low in 3 years time (2.4%).


Past Performance

How has Teladoc Health performed over the past 5 years?

-52.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TDOC is currently unprofitable.

Growing Profit Margin: TDOC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TDOC is unprofitable, and losses have increased over the past 5 years at a rate of 52.6% per year.

Accelerating Growth: Unable to compare TDOC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TDOC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (16.1%).


Return on Equity

High ROE: TDOC has a negative Return on Equity (-5.08%), as it is currently unprofitable.


Financial Health

How is Teladoc Health's financial position?


Financial Position Analysis

Short Term Liabilities: TDOC's short term assets ($1.2B) exceed its short term liabilities ($302.1M).

Long Term Liabilities: TDOC's short term assets ($1.2B) do not cover its long term liabilities ($1.4B).


Debt to Equity History and Analysis

Debt Level: TDOC's net debt to equity ratio (2.5%) is considered satisfactory.

Reducing Debt: TDOC's debt to equity ratio has reduced from 18.4% to 7.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TDOC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TDOC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Teladoc Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TDOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TDOC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TDOC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TDOC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TDOC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.9yrs

Average management tenure


CEO

Jason Gorevic (49 yo)

12.58yrs

Tenure

US$8,455,584

Compensation

Mr. Jason Nathanial Gorevic has been Chief Executive Officer at Teladoc Health, Inc. (formerly known as Teladoc, Inc.) (Formerly TelaDoc Medical Services Inc.) since June 2009. Mr. Gorevic served as Direct...


CEO Compensation Analysis

Compensation vs Market: Jason's total compensation ($USD8.46M) is about average for companies of similar size in the US market ($USD11.47M).

Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TDOC's management team is seasoned and experienced (6.9 years average tenure).


Board Members

Experienced Board: TDOC's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TDOC insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.4%.


Top Shareholders

Company Information

Teladoc Health, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Teladoc Health, Inc.
  • Ticker: TDOC
  • Exchange: NYSE
  • Founded: 2002
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: US$11.531b
  • Shares outstanding: 160.09m
  • Website: https://www.teladochealth.com

Number of Employees


Location

  • Teladoc Health, Inc.
  • 2 Manhattanville Road
  • Suite 203
  • Purchase
  • New York
  • 10577
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/26 01:04
End of Day Share Price2022/01/25 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.